Archive · 2 Dec 2025
Wockhardt Shares Surge 18% on USFDA NDA Acceptance
Wockhardt is a big pharmaceutical company in India.
They made a new antibiotic called Zaynich.
The USFDA, which is like a big boss for medicines in the US, accepted their application to sell this new drug.
This is a really big deal because it's the first time an Indian company has had a new drug like this accepted by the USFDA.
The company has been working on this drug for a long time, since 2011.
Because of this good news, the company's stock price went up by 18%.
The USFDA also gave the drug a special status called 'Fast Track' because it can help with important medical needs.
This means the USFDA will look at it quickly.
It's a big achievement for Wockhardt and for India's medicine industry.
Wockhardt Ltd's shares surged 18% after USFDA accepted NDA for Zaynich antibiotic.
This is the first time an Indian pharma company has had an NDA for a New Chemical Entity accepted by the USFDA.
Zaynich has been granted Fast Track designation by the USFDA for addressing urgent medical needs.
The drug has undergone extensive research and development since 2011.
Wockhardt highlighted the stringent scientific and regulatory thresholds met for this achievement.
- Who
- Wockhardt Ltd
- What
- USFDA acceptance of NDA for Zaynich antibiotic
- When
- Monday (stock price increase)
- Where
- India (company), United States (USFDA)
- Why
- Significant milestone for Indian pharmaceutical industry, potential to address urgent medical needs
- Company
- Wockhardt Ltd
- Stock Price Increase
- 18%
- Highest Stock Price
- Rs 1,382.85
- Drug Name
- Zaynich
- Regulatory Body
- USFDA
- Application Type
- New Drug Application (NDA)
- Designation
- Fast Track
- Development Start Year
- 2011
Sources
Wockhardt shares zoom over 12% on this USFDA approval
Wockhardt share price jumps over 19% after US FDA accepts new drug application for Zaynich
Markets lose momentum after hitting lifetime highs: Nifty closes below 26,200; Bajaj Finance, Sun Pharma see sharp cut
US FDA accepts Wockhardt’s new drug application for novel antibiotic Zaynich
Wockhardt shares extend rally as USFDA accepts NDA for antibiotic Zaynich
